LIVERPOOL, England — A novel intra-articular injection of allogeneic gene-modified cell therapy was associated with significant improvements in International Knee Documentation Committee scores compared with placebo, according to findings presented here.
Bumsup Lee, PhD, president and CEO of TissueGene Inc., presented findings for the Invossa-k (Kolon TissueGene) injection for the treatment of knee OA. The injection is approved in Korea and is in phase 3 trials in the US. “We make one single injection into the intra-articular joint,” he said.
In the current study, 78 patients
Original Article: Novel intra-articular gene therapy improves function, pain in knee OA